Literature DB >> 15498533

Induced sputum in cystic fibrosis: within-week reproducibility of inflammatory markers.

Argyrios A Smountas1, Larry C Lands, Shawn R Mohammed, Vijaylaxmi Grey.   

Abstract

UNLABELLED: Analysis of induced sputum has provided significant insight into the inflammatory response in chronic respiratory diseases such as asthma. The thick, tenacious nature of cystic fibrosis (CF) sputum presents certain challenges to such evaluation. We describe the development of a methodology to assess CF sputum, and the within-week reproducibility (to limit the possibility of any change in clinical status) of cellular and inflammatory markers.
METHODS: Seventeen young adults [9 males, 8 females, mean age 24 (5), median (quartile range) years, percentage of predicted FEV(1) = 64.0 (18.0%)] with CF underwent sputum inductions on the Monday and Thursday of the same week. Patients were pretreated with 400 microg salbutamol and subsequently inhaled 5% saline via a breath enhanced nebulizer. Every 3-min nebulization was interrupted to allow for expectoration of sputum into a polypropylene pot. Sputum samples were dispersed with a solution of dithiothreitol (DTT) and deoxyribonuclease to allow for analysis of total cell count (TCC) and percentage neutrophils (%Neut). Measurement of tumor necrosis factor-alpha (TNF-alpha), interleukin-8 (IL-8), and neutrophil elastase was performed on samples dispersed with DTT alone.
RESULTS: There were no significant differences between the measurements taken in the same week. Values for Day 1 versus Day 2 were as follows: TCC 20.8 (6.4) vs. 17.6 (2.5) x 10(6) cells/ml; %Neut: 94.1 (0.0) vs. 95.4 (0.5) %; TNF-alpha 7.5 (26.0) vs. 21.0 (44.0) pg/ml; IL-8 610.0 (422.0) vs. 524.0 (587.0) ng/ml and neutrophil elastase 110.0 (19.75) vs. 49.75 (60.75) microM. High intraclass correlation coefficients (ICC) for TCC, %Neut, TNF-alpha IL-8 and neutrophil elastase were found (ICC = 0.76, 0.82, 0.93, 0.82, 0.74, respectively).
CONCLUSIONS: The method developed here for the analysis of CF sputum shows good reproducibility and can be used to evaluate therapeutic interventions in patients with cystic fibrosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15498533     DOI: 10.1016/j.clinbiochem.2004.07.008

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  9 in total

Review 1.  Advancing outcome measures for the new era of drug development in cystic fibrosis.

Authors:  Nicole Mayer-Hamblett; Bonnie W Ramsey; Richard A Kronmal
Journal:  Proc Am Thorac Soc       Date:  2007-08-01

2.  Down-regulation of cytokine-induced interleukin-8 requires inhibition of p38 mitogen-activated protein kinase (MAPK) via MAPK phosphatase 1-dependent and -independent mechanisms.

Authors:  Nurlan Dauletbaev; Daniel Eklove; Nadir Mawji; Michele Iskandar; Sergio Di Marco; Imed-Eddine Gallouzi; Larry C Lands
Journal:  J Biol Chem       Date:  2011-03-15       Impact factor: 5.157

Review 3.  Sputum biomarkers of inflammation in cystic fibrosis lung disease.

Authors:  Scott D Sagel; James F Chmiel; Michael W Konstan
Journal:  Proc Am Thorac Soc       Date:  2007-08-01

Review 4.  Novel outcome measures for clinical trials in cystic fibrosis.

Authors:  Harm A W M Tiddens; Michael Puderbach; Jose G Venegas; Felix Ratjen; Scott H Donaldson; Stephanie D Davis; Steven M Rowe; Scott D Sagel; Mark Higgins; David A Waltz
Journal:  Pediatr Pulmonol       Date:  2014-12-30

5.  Phase I Studies of Acebilustat: Biomarker Response and Safety in Patients with Cystic Fibrosis.

Authors:  J S Elborn; A Horsley; G MacGregor; D Bilton; R Grosswald; S Ahuja; E B Springman
Journal:  Clin Transl Sci       Date:  2016-11-02       Impact factor: 4.689

6.  Phase I Studies of Acebilustat: Pharmacokinetics, Pharmacodynamics, Food Effect, and CYP3A Induction.

Authors:  J S Elborn; L Bhatt; R Grosswald; S Ahuja; E B Springman
Journal:  Clin Transl Sci       Date:  2016-10-28       Impact factor: 4.689

7.  Prospective multicenter randomized patient recruitment and sample collection to enable future measurements of sputum biomarkers of inflammation in an observational study of cystic fibrosis.

Authors:  Theodore G Liou; Frederick R Adler; Natalia Argel; Fadi Asfour; Perry S Brown; Barbara A Chatfield; Cori L Daines; Dixie Durham; Jessica A Francis; Barbara Glover; Theresa Heynekamp; John R Hoidal; Judy L Jensen; Ruth Keogh; Carol M Kopecky; Noah Lechtzin; Yanping Li; Jerimiah Lysinger; Osmara Molina; Craig Nakamura; Kristyn A Packer; Katie R Poch; Alexandra L Quittner; Peggy Radford; Abby J Redway; Scott D Sagel; Shawna Sprandel; Jennifer L Taylor-Cousar; Jane B Vroom; Ryan Yoshikawa; John P Clancy; J Stuart Elborn; Kenneth N Olivier; David R Cox
Journal:  BMC Med Res Methodol       Date:  2019-04-26       Impact factor: 4.615

Review 8.  High-Dose Ibuprofen in Cystic Fibrosis.

Authors:  Larry C Lands; Nurlan Dauletbaev
Journal:  Pharmaceuticals (Basel)       Date:  2010-07-13

9.  Airway inflammation and anti-protease defences rapidly improve during treatment of an acute exacerbation of COPD.

Authors:  Sushil Pant; Eugene H Walters; Anne Griffiths; Richard Wood-Baker; David P Johns; David W Reid
Journal:  Respirology       Date:  2009-05       Impact factor: 6.424

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.